2019 IPO
Exicure Stock
Exicure is developing a new class of immunomodulatory and gene silencing drugs against validated targets.
Sign up today and learn more about Exicure Stock
Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.
About Exicure Stock
Exicure is Formerly Known as AuraSense Therapeuticsis. Exicure is developing a new class of immunomodulatory and gene silencing drugs against validated targets. Our 3-dimensional, spherical nucleic acid (SNA™) architecture unlocks the potential of nucleic acid therapeutics in multiple organs. Our lead programs address diseases from inflammatory disorders to oncology. SNA constructs overcome one of the most difficult obstacles to nucleic acid therapeutics: safe and effective delivery into cells and tissues. SNA constructs exhibit unparalleled transfection efficiency into numerous cell and tissue types including the skin without carriers or transfection agents. Moreover, SNAs can be used as potent immunotherapeutic agents for the treatment of cancer or infectious disease.
Funding History
| December 2009 | $2.5M |
|---|---|
| December 2011 | $5.4M |
| July 2013 | $0 |
| June 2014 | $13.6M |
| February 2015 | $4.5M |
| October 2015 | $14.8M |
| January 2016 | $0 |
| September 2017 | $20.0M |
Management
COO
David A. Giljohann
CTO
Sergei Gryaznov
Founder
Chad A. Mirkin
Founder
C. Shad Thaxton
Director Program Management
Weston Daniel
EquityZen does not have an affiliation with, formal relationship with, or endorsement from any companies featured above. This profile is based on publicly available information and is intended to be informative in nature.
Some data provided by Crunchbase
EquityZen Recognized As:
